COYA — Coya Therapeutics Cashflow Statement
0.000.00%
- $129.31m
- $101.18m
- $3.55m
Annual cashflow statement for Coya Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.733 | -4.89 | -12.2 | -7.99 | -14.9 |
| Depreciation | |||||
| Non-Cash Items | 0.264 | 0.233 | 4.23 | 1.42 | 2.69 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.078 | 0.739 | 0.752 | -4.64 | 1.88 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.391 | -3.9 | -7.24 | -11.2 | -10.3 |
| Capital Expenditures | 0 | -0.137 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -0.525 | -0.543 | -0.025 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | -0.137 | -0.525 | -0.543 | -0.025 |
| Financing Cash Flow Items | 0 | -0.341 | -1.11 | 0 | -0.121 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.11 | -0.341 | 9.36 | 38.4 | 16 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.72 | -4.38 | 1.59 | 26.7 | 5.71 |